-
Something wrong with this record ?
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial
SD. Solomon, JW. Ostrominski, M. Vaduganathan, B. Claggett, PS. Jhund, AS. Desai, CSP. Lam, B. Pitt, M. Senni, SJ. Shah, AA. Voors, F. Zannad, IZ. Abidin, MA. Alcocer-Gamba, JJ. Atherton, J. Bauersachs, CS. Ma, CE. Chiang, O. Chioncel, V. Chopra,...
Language English Country England, Great Britain
Document type Journal Article, Randomized Controlled Trial, Multicenter Study
Grant support
Bayer
NLK
Medline Complete (EBSCOhost)
from 2000-03-01 to 1 year ago
Wiley Free Content
from 1999 to 1 year ago
PubMed
38733212
DOI
10.1002/ejhf.3266
Knihovny.cz E-resources
- MeSH
- Mineralocorticoid Receptor Antagonists * therapeutic use MeSH
- Double-Blind Method MeSH
- Ventricular Function, Left physiology drug effects MeSH
- Glomerular Filtration Rate physiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Naphthyridines * therapeutic use MeSH
- Natriuretic Peptide, Brain blood MeSH
- Aged MeSH
- Heart Failure * physiopathology drug therapy MeSH
- Stroke Volume * physiology MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
AIMS: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. METHODS AND RESULTS: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m2, elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34-84%); 36% of participants had a LVEF <50% and 64% had a LVEF ≥50%. The median N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 1041 (interquartile range 449-1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large-scale HFmrEF/HFpEF trials, FINEARTS-HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors than previous trials. CONCLUSIONS: FINEARTS-HF has enrolled a broad range of high-risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.
Bayer plc Research and Development Pharmaceuticals Reading UK
Bayer Research and Development Pharmaceuticals Hoofddorp The Netherlands
Bayer Research and Development Pharmaceuticals São Paulo Brazil
Bayer Research and Development Pharmaceuticals Whippany NJ USA
Beijing Anzhen Hospital Capital Medical University Beijing China
Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston MA USA
Cardiovascular Division Instituto de Pesquisa Clínica de Campinas Campinas Brazil
Centro Cardiovascular Colombiano Clínica Santa María Antioquia Colombia
Centro de Estudios Clínicos de Querétaro Querétaro Mexico
Christchurch Heart Institute Department of Medicine University of Otago Christchurch New Zealand
Clinical Cardiology Heart Failure and Research Max Super Specialty Hospital New Delhi India
Department of Cardiology and Angiology Hannover Medical School Hannover Germany
Department of Cardiology Herlev Gentofte University Hospital Hellerup Denmark
Department of Cardiology Hospital Group Twente Almelo The Netherlands
Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic
Department of Cardiology University of Brescia and ASST 'Spedali Civili' Hospital Brescia Italy
Department of Medicine University of Minnesota Minneapolis VA Health Care System Minneapolis MN USA
Department of Noninvasive Cardiology National Cardiology Hospital Sofia Bulgaria
Division of Cardiac Surgery St Michael's Hospital University of Toronto Toronto ON Canada
Division of Cardiology Department of Internal Medicine Medical University of Graz Graz Austria
Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD USA
Division of Cardiology Severance Hospital Yonsei University Health System Seoul South Korea
Dokuz Eylul University Medical Faculty Cardiology Department Izmir Turkey
Faculty of Medicine Comenius University Bratislava Slovakia
Heart and Vascular Center Semmelweis University Budapest Hungary
Heart Centre Turku University Hospital Turku Finland
Heart Failure Unit Kaplan Medical Center Rehovot Israel
Hospital Cardiologico Aguascalientes Aguascalientes Mexico
Kawaguchi Cardiovascular and Respiratory Hospital Saitama Japan
Latvian Center of Cardiology Pauls Stradins Clinical University Hospital Riga Latvia
Li Ka Shing Institute of Health Sciences The Chinese University of Hong Kong Hong Kong China
National Heart Centre Singapore and Duke National University of Singapore Singapore Singapore
Northwestern University Feinberg School of Medicine Chicago IL USA
Saint Luke's Mid America Heart Institute University of Missouri Kansas City Kansas City MO USA
Section of Cardiology Max Rady College of Medicine University of Manitoba Winnipeg MB Canada
Taipei Veterans General Hospital Taipei Taiwan
Universidad Nacional de Córdoba Córdoba Argentina
Université de Lorraine Inserm Clinical Investigation Centre CHU Nancy France
University Bicocca Milan Italy and Papa Giovanni XXIII Hospital Bergamo Italy
University Clinic of Lomonosov Moscow State University Moscow Russia
University Medical Center Groningen Groningen The Netherlands
University of Malaya Kuala Lumpur Malaysia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013638
- 003
- CZ-PrNML
- 005
- 20240905133842.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ejhf.3266 $2 doi
- 035 __
- $a (PubMed)38733212
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Solomon, Scott D $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000336989597
- 245 10
- $a Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial / $c SD. Solomon, JW. Ostrominski, M. Vaduganathan, B. Claggett, PS. Jhund, AS. Desai, CSP. Lam, B. Pitt, M. Senni, SJ. Shah, AA. Voors, F. Zannad, IZ. Abidin, MA. Alcocer-Gamba, JJ. Atherton, J. Bauersachs, CS. Ma, CE. Chiang, O. Chioncel, V. Chopra, J. Comin-Colet, G. Filippatos, C. Fonseca, G. Gajos, S. Goland, E. Goncalvesová, SM. Kang, T. Katova, MN. Kosiborod, G. Latkovskis, AP. Lee, GCM. Linssen, G. Llamas-Esperón, V. Mareev, FA. Martinez, V. Melenovský, B. Merkely, S. Nodari, MC. Petrie, CI. Saldarriaga, JFK. Saraiva, N. Sato, M. Schou, K. Sharma, R. Troughton, JA. Udell, H. Ukkonen, O. Vardeny, S. Verma, D. von Lewinski, LG. Voronkov, MB. Yilmaz, S. Zieroth, J. Lay-Flurrie, I. van Gameren, F. Amarante, P. Viswanathan, JJV. McMurray
- 520 9_
- $a AIMS: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. METHODS AND RESULTS: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m2, elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34-84%); 36% of participants had a LVEF <50% and 64% had a LVEF ≥50%. The median N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 1041 (interquartile range 449-1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large-scale HFmrEF/HFpEF trials, FINEARTS-HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors than previous trials. CONCLUSIONS: FINEARTS-HF has enrolled a broad range of high-risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a srdeční selhání $x patofyziologie $x farmakoterapie $7 D006333
- 650 12
- $a tepový objem $x fyziologie $7 D013318
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a antagonisté mineralokortikoidních receptorů $x terapeutické užití $7 D000451
- 650 12
- $a naftyridiny $x terapeutické užití $7 D009287
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a funkce levé komory srdeční $x fyziologie $x účinky léků $7 D016277
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a hodnoty glomerulární filtrace $x fyziologie $7 D005919
- 650 _2
- $a natriuretický peptid typu B $x krev $7 D020097
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Ostrominski, John W $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000228669414
- 700 1_
- $a Vaduganathan, Muthiah $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Claggett, Brian $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Jhund, Pardeep S $u BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
- 700 1_
- $a Desai, Akshay S $u Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Lam, Carolyn S P $u National Heart Centre Singapore & Duke-National University of Singapore, Singapore, Singapore
- 700 1_
- $a Pitt, Bertram $u University of Michigan, School of Medicine, Ann Arbor, MI, USA
- 700 1_
- $a Senni, Michele $u University Bicocca Milan, Italy, and, Papa Giovanni XXIII Hospital, Bergamo, Italy
- 700 1_
- $a Shah, Sanjiv J $u Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 700 1_
- $a Voors, Adriaan A $u University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Zannad, Faiez $u Université de Lorraine, Inserm Clinical Investigation Centre, CHU, Nancy, France
- 700 1_
- $a Abidin, Imran Zainal $u University of Malaya, Kuala Lumpur, Malaysia
- 700 1_
- $a Alcocer-Gamba, Marco Antonio $u Centro de Estudios Clínicos de Querétaro, Querétaro, Mexico
- 700 1_
- $a Atherton, John J $u Cardiology Research Department, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia
- 700 1_
- $a Bauersachs, Johann $u Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Ma, Chang-Sheng $u Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- 700 1_
- $a Chiang, Chern-En $u Taipei Veterans General Hospital, Taipei, Taiwan
- 700 1_
- $a Chioncel, Ovidiu $u Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', University of Medicine Carol Davila, Bucharest, Romania
- 700 1_
- $a Chopra, Vijay $u Clinical Cardiology, Heart Failure and Research, Max Super Specialty Hospital, New Delhi, India
- 700 1_
- $a Comin-Colet, Josep $u Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute, CIBER-CV, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
- 700 1_
- $a Filippatos, Gerasimos $u Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Fonseca, Cândida $u Department of Internal Medicine, Hospital São Francisco Xavier, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal
- 700 1_
- $a Gajos, Grzegorz $u Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland
- 700 1_
- $a Goland, Sorel $u Heart Failure Unit, Kaplan Medical Center, Rehovot, Israel
- 700 1_
- $a Goncalvesová, Eva $u Faculty of Medicine, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Kang, Seok-Min $u Division of Cardiology, Severance Hospital, Yonsei University Health System, Seoul, South Korea
- 700 1_
- $a Katova, Tzvetana $u Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria
- 700 1_
- $a Kosiborod, Mikhail N $u Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA
- 700 1_
- $a Latkovskis, Gustavs $u Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia
- 700 1_
- $a Lee, Alex Pui-Wai $u Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Linssen, Gerard C M $u Department of Cardiology, Hospital Group Twente, Almelo, The Netherlands
- 700 1_
- $a Llamas-Esperón, Guillermo $u Hospital Cardiologico Aguascalientes, Aguascalientes, Mexico
- 700 1_
- $a Mareev, Vyacheslav $u University Clinic of Lomonosov Moscow State University, Moscow, Russia
- 700 1_
- $a Martinez, Felipe A $u Universidad Nacional de Córdoba, Córdoba, Argentina
- 700 1_
- $a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Merkely, Béla $u Heart and Vascular Center, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Nodari, Savina $u Department of Cardiology, University of Brescia and ASST 'Spedali Civili' Hospital, Brescia, Italy
- 700 1_
- $a Petrie, Mark C $u BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
- 700 1_
- $a Saldarriaga, Clara Inés $u Centro Cardiovascular Colombiano, Clínica Santa María, Antioquia, Colombia
- 700 1_
- $a Saraiva, Jose Francisco Kerr $u Cardiovascular Division, Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil
- 700 1_
- $a Sato, Naoki $u Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan
- 700 1_
- $a Schou, Morten $u Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark
- 700 1_
- $a Sharma, Kavita $u Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 700 1_
- $a Troughton, Richard $u Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand
- 700 1_
- $a Udell, Jacob A $u Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Ukkonen, Heikki $u Heart Centre, Turku University Hospital, Turku, Finland
- 700 1_
- $a Vardeny, Orly $u Department of Medicine, University of Minnesota, Minneapolis VA Health Care System, Minneapolis, MN, USA
- 700 1_
- $a Verma, Subodh $u Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a von Lewinski, Dirk $u Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Voronkov, Leonid G $u National Scientific Center, Strazhesko Institute of Cardiology, National Academy of Medical Sciences, Kyiv, Ukraine
- 700 1_
- $a Yilmaz, Mehmet Birhan $u Dokuz Eylul University Medical Faculty, Cardiology Department, Izmir, Turkey
- 700 1_
- $a Zieroth, Shelley $u Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
- 700 1_
- $a Lay-Flurrie, James $u Bayer plc, Research & Development, Pharmaceuticals, Reading, UK
- 700 1_
- $a van Gameren, Ilse $u Bayer, Research & Development, Pharmaceuticals, Hoofddorp, The Netherlands
- 700 1_
- $a Amarante, Flaviana $u Bayer, Research & Development, Pharmaceuticals, São Paulo, Brazil
- 700 1_
- $a Viswanathan, Prabhakar $u Bayer, Research & Development, Pharmaceuticals, Whippany, NJ, USA
- 700 1_
- $a McMurray, John J V $u BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
- 773 0_
- $w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 26, č. 6 (2024), s. 1334-1346
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38733212 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133836 $b ABA008
- 999 __
- $a ok $b bmc $g 2143435 $s 1225504
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 26 $c 6 $d 1334-1346 $e 20240511 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
- GRA __
- $p Bayer
- LZP __
- $a Pubmed-20240725
